Date: 2011-02-07
Type of information: Granting of a patent
Product name: MOR103
Compound: MOR103
Therapeutic area:
Action mechanism: monoclonal antibody. MOR103 is a human monoclonal antibody to GM-CSF (granulocyte macrophage-colony stimulating factor).
Company: Morphosys (Germany)
Disease:
Latest news:
Patents: * On February 7, 2011, MorphoSys announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's most advanced proprietary compound MOR103. The new patent (US 7,867,495) covers MorphoSys's HuCAL antibody against GM-CSF as well as pharmaceutical compositions comprising the same, and has a scheduled expiry date in 2026, not including any potential extensions. This newly issued patent complements a US patent granted in 2008 covering medical uses of antibodies against GM-CSF, to which MorphoSys has exclusive access under a license agreement with the University of Melbourne. Together, the two patent families provide strong intellectual property protection for the MOR103 program.
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news:
